DIVA Laboratories, Ltd. (4153.TWO)

TWD 38.75

(-1.77%)

EBITDA Summary of DIVA Laboratories, Ltd.

  • DIVA Laboratories, Ltd.'s latest annual EBITDA in 2023 was 100.31 Million TWD , down -24.16% from previous year.
  • DIVA Laboratories, Ltd.'s latest quarterly EBITDA in 2024 Q3 was 22.54 Million TWD , down -44.13% from previous quarter.
  • DIVA Laboratories, Ltd. reported an annual EBITDA of 132.27 Million TWD in 2022, up 244.44% from previous year.
  • DIVA Laboratories, Ltd. reported an annual EBITDA of 38.4 Million TWD in 2021, down -50.59% from previous year.
  • DIVA Laboratories, Ltd. reported a quarterly EBITDA of 37.03 Million TWD for 2024 Q1, up 24.98% from previous quarter.
  • DIVA Laboratories, Ltd. reported a quarterly EBITDA of 40.34 Million TWD for 2024 Q2, up 8.93% from previous quarter.

Annual EBITDA Chart of DIVA Laboratories, Ltd. (2023 - 2019)

Historical Annual EBITDA of DIVA Laboratories, Ltd. (2023 - 2019)

Year EBITDA EBITDA Growth
2023 100.31 Million TWD -24.16%
2022 132.27 Million TWD 244.44%
2021 38.4 Million TWD -50.59%
2020 77.72 Million TWD -7.55%
2019 84.06 Million TWD 0.0%

Peer EBITDA Comparison of DIVA Laboratories, Ltd.

Name EBITDA EBITDA Difference
BIONET Corp. 147.09 Million TWD 31.802%
Genetics Generation Advancement Corp. 50.6 Million TWD -98.239%
Welgene Biotech Co.,Ltd. 26.83 Million TWD -273.809%
Puriblood Medical Co., Ltd. -44.01 Million TWD 327.91%
TFBS Bioscience Inc. 64.15 Million TWD -56.372%